Physician entrepreneurs come in several basic flavors and medicine needs to change to make room for them.
The young and the restless These are the millenials and others who are medical students, residents, fellows and those who have been in practice less than 5 years. While I think stereotyping generations is stupid , work-life balance, debt repayment and lack of loyalty to an employer or career seems to figure into the psychographic calculus
GlycoMimetics, Inc. (NASDAQ: GLYC) announced that preclinical data on its novel E-selectin antagonist drug candidate GMI-1271, shared via an oral presentation at the 57th American Society of Hematology (ASH) annual meeting, showed the compound could be used in combination with G-CSF (filgrastim) to mobilize and enrich progenitor T cells known as T memory stem (Tscm) and T central memory (Tcm) cells, which provide improved reconstitution and persistence. The company also announced that the first healthy participant has been treated with an intravenous (IV) formulation of GMI-1271 in a Phase 1, multiple-dose clinical study to evaluate the investigational drug’s ability to mobilize and enrich Tscm or Tcm cells. In addition, the trial will evaluate safety and tolerability of the drug, alone and in combination with filgrastim, a treatment for neutropenia that is approved by the U.S. Food and Drug Administration (FDA).
Google Life Sciences got a rebrand today: It’s now called Verily. A new site is up as well to illustrate the company’s emphasis on wielding technology “to create a true picture of human health” – and “effecting prevention.”
Just as Google formed parent company “Alphabet” earlier this year, it’s clearly sticking to a literary theme with “verily,” which is a florid, Shakespearean way to say “truth, truly, confidently.”
Paris-based venture capital firm, Sofinnova Partners, has closed its Sofinnova Capital VIII fund with €300 million ($324 million) that will be dedicated toward adding 15 to 20 more biotech companies to its portfolio, two thirds of which will reportedly be in Europe, the rest in North America.
Back in 2012, the firm raised €240m, and with this new fund it brings the current amount under management at Sofinnova Partners to €1.5 billion ($1.6 billion). The company’s focus will remain in the biopharmaceutical and medical device sectors.
Holiday Celebration Time is Coming! Join us as we remember this amazing year of WIB-DC/Baltimore on December 15, 2015, from 6:00 p.m. to 8:30 p.m., at Paladar Latin Kitchen & Rum Bar in Rockville. Food, drinks, and music will be provided – and of course networking opportunities with all our members and guests. Also the WIB scholarship award winner sponsored from our chapter will be announced!
Not only are we thankful for all you members’ support and engagement, we are also looking forward to hearing your feedback for what we can do better in 2016!
Standing in a virtual-reality lab at the University of Maryland here, Ramani Duraiswami passed around a standard pair of headphones.
Music played over them — but to the wearer, the source of the sound seemed to move around the room. As the music quieted down, it sounded as if it came from farther away. As it got louder on one side of the headset, it sounded as if it came from that side. “We’re able to perceive the world in all dimensions using our ears,” said Mr. Duraiswami, a computer-science professor and co-founder of the start-up company VisiSonics.
Rockville-based Sucampo Pharmaceuticals Inc. finalized its acquisition of the Japanese biotech R-Tech Ueno for $275 million, officials said Monday.
In August, Sucampo (NASDAQ: SCMP) made a $278 million all-cash offer to acquire R-Tech Ueno, a Japanese pharmaceutical company that manufactures Amitiza, Sucampo’s flagship drug that eases drug-related constipation using fatty acid-derived compounds known as prostones.
Care Progress, LLC announced today that it was awarded a Phase II Small Business Innovation Research (“SBIR”) grant from the National Science Foundation (“NSF”). The Phase II award will fund the further development of the company’s CarePrompter© software platform, which improves outcomes for cancer patients as well as workflow and profitability for oncology departments and practices.
“It provides support for further development of our critical technology. With this award, we will accelerate our plans to develop additional functionality for cancer providers and patients within a large and growing market.” Tweet this “This Phase II SBIR award is a significant milestone for us,” said Howard Isenstein, Founder of Care Progress. “It provides support for further development of our critical technology. With this award, we will accelerate our plans to develop additional functionality for cancer providers and patients within a large and growing market.”
PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that, upon the recommendation of the European Medicines Agency (EMA), the European Commission has granted the Orphan Drug designation to PharmaCyte’s subsidiary, PharmaCyte Biotech Europe Limited, for PharmaCyte’s pancreatic cancer treatment. Receiving Orphan Drug designation for PharmaCyte’s pancreatic cancer treatment carries with it 10 years of marketing exclusivity in countries in the European Union. In addition, the EMA provides special assistance in the development of PharmaCyte’s treatment for pancreatic cancer.
The Orphan Drug designation in the European Union is given to drugs for life-threatening diseases with low prevalence, or that make it unlikely an investment in a drug to treat a life-threatening disease would be cost justified, and that demonstrate there is a significant benefit to patients being treated with the drug.
With payers increasingly rewarding value and expectations of the customer experience on the rise among all stakeholders, one of the key ways pharmas will differentiate their products is through understanding their customers’ pain points and providing tools and services that address them. For today’s physician, EHRs are a real pain, and prior authorizations are another. So we were interested to learn of a Avhana Health, a startup that is currently piloting a cloud-based clinical decision support system that sits on top of four of the big EHR systems – Epic, Allscripts, AthenaHealth and Greenway.
